TipRanks
Go Ultimate55% OFF

Naturhouse Health (NTH) AI Stock Analysis

ES:NTH

Naturhouse Health

(BME:NTH)

Select Model
Rating:77Outperform
Price Target:EUR 3.00â–²(32.16% Upside)
Action:reiterated
Date:08/07/26

The score is driven primarily by strong financial performance, led by a very healthy balance sheet and reliable cash generation. Technicals are supportive but not especially strong, while valuation is helped by the high dividend yield and reasonable P/E ratio; revenue decline remains the main risk.

Positive Factors
High profitability and marginsConsistently high margins indicate a durable ability to generate operating profit per unit of revenue, supporting cash flow and dividend capacity even if top-line growth slows. Strong margin structure preserves operating leverage and allows the company to sustain profitability through cyclical pressures.
Negative Factors
Steep multi-year revenue declineA pronounced and persistent top-line contraction undermines scale economics for product sales and center profitability, threatening future margin sustainability and royalty/fee income. Continued revenue erosion can erode FCF and make it harder to maintain investment in the network or product development.

Naturhouse Health (NTH) vs. iShares MSCI Spain ETF (EWP)

-10%0%10%20%30%40%ES:NTH+19.47%EWP+15.75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 136.09M
Dividend Yield
13.22%
Average Volume (3M)
41.33K
Price to Earnings (P/E)
15.6
Beta (1Y)
0.27
Revenue Growth
-6.06%
EPS Growth
-15.89%
Country
Spain
Employees
168
Sector
General
Sector Strength
55
Industry
Packaged Foods

Naturhouse Health Business Overview & Revenue Model

Company Description

Naturhouse Health, S.A. is a prominent entity in the global nutrition and weight management sector, maintaining a significant presence across Spain, Italy, France, Poland, and numerous other international markets. The company provides a diverse array...

How the Company Makes Money

Naturhouse primarily makes money through (1) product sales and (2) network-related income tied to its branded centers. Product revenue is generated from selling dietetic and nutritional items (e.g., supplements and other weight-management/wellness pr...

Naturhouse Health Financial Statement Overview

Summary

Strong overall financial profile: the balance sheet is exceptionally solid with low leverage and high ROE, and cash flow is consistently positive and supportive of earnings. The main drag is multi-year revenue decline, which keeps the score below the top tier despite healthy margins and stable profits.

Income Statement

72Positive

Balance Sheet

88Very Positive

Cash Flow

80Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue44.91M47.63M49.42M50.41M52.40M57.59M
Gross Profit31.84M12.94M35.46M25.11M37.48M41.26M
EBITDA11.11M14.45M15.63M17.93M15.61M20.80M
Net Income8.61M10.09M9.86M11.29M9.63M13.36M
Balance Sheet
Total Assets29.96M33.43M42.59M48.85M42.82M49.00M
Cash, Cash Equivalents and Short-Term Investments10.43M14.57M21.67M27.10M14.78M27.25M
Total Debt6.29M3.43M4.27M5.05M5.38M4.37M
Total Liabilities14.65M15.68M10.91M18.21M14.96M12.92M
Stockholders Equity15.31M17.75M31.68M30.63M27.81M36.02M
Cash Flow
Free Cash Flow10.74M11.67M11.22M20.38M6.13M16.12M
Operating Cash Flow10.61M12.15M11.56M20.95M7.10M16.17M
Investing Cash Flow423.00K-420.00K862.00K-459.00K-5.22M-4.27M
Financing Cash Flow-22.96M-18.95M-16.10M-7.70M-16.98M-6.27M

Naturhouse Health Technical Analysis

Technical Analysis SentimentNeutral
Last Price2.27

Price Trends

50DMA2.35Negative
100DMA2.44Negative
200DMA2.46Negative

Market Momentum

MACD-0.02Negative
RSI50.17Neutral
STOCH39.68Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:NTH, the sentiment is Neutral. The current price of 2.27 is above the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.35, and below the 200-day MA of 2.46, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 39.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:NTH.

Naturhouse Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

ES:NTH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:NTHES:NTH77OutperformEUR 136.09M15.6352.07%13.22%-6.06%-15.89%
ES:EBROES:EBRO73OutperformEUR 2.74B12.269.51%3.01%-4.44%13.17%
ES:PUIGES:PUIG72OutperformEUR 10.85B18.5214.66%2.19%3.63%-10.79%
ES:DIAES:DIA58NeutralEUR 2.63B15.60113.16%―2.05%117.98%
ES:OLEES:OLE57NeutralEUR 170.50M9.328.23%―-15.27%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ES:PVAES:PVA38UnderperformEUR 6.35M-49.112.00%―2.56%-117.93%

* General Sector Average

Performance Comparison

0%50%100%150%ES:NTHES:DIAES:EBROES:PVAES:OLEES:PUIGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
ES:NTH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ES:NTHNaturhouse Health2.270.3820.04%
ES:DIADISTRIBUIDORA INTERNACIONAL DE ALIMENTACION45.4017.2060.99%
ES:EBROEBRO FOODS17.780.653.82%
ES:PVAPescanova SA0.22-0.07-24.05%
ES:OLEDEOLEO S.A.0.340.1579.47%
ES:PUIGPuig Brands, S.A.19.264.7432.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 04, 2026